Infective endocarditis is a serious disease, which almost 2000 people are affected each year in France, a quarter of them will die. This infection is usually of bacterial origin and affects the heart tissue or implanted medical devices such as prostheses, pacemakers or defibrillators. In 2002, of cases, the treatment for this condition a surgical procedure. Despite advances in the therapeutic resources available to had mortality associated with this disease for many years, not decreased.
After Bita Moghaddam, a professor of neuroscience and psychiatry, who led the study, in addition to its clinical utility, may post – stimulus release activated are used to explain how brief events neurons activate for short periods to time, the brain function influence long after the events. For example, it can be used to explain smells like freshly baked cookies could or childhood memories of the time with a beloved grandparent, what a person wallow too long in memories after the smell is gone and take the unplanned or impulsive action of baking purchase cookies will remember.About ACTEMRA ACTEMRA is the first humanized interleukin-6 receptor has monoclonal antibody. Studies indicate in that the reduction of activity of IL-6, one of several important cytokines hit in inflammatory process are In June 2005 inflammation of the joints and relieve particular systemic effects of RA. The extensive clinical development programs conducted by the Roche includes five clinical study and has been inscribed more than 4,000 patients in 41 countries, including the United States. Five phase III trials are completed and have met their primary endpoints. The LITHE study to assess ACTEMRA is in the RA is a going two-year study and is scheduled Reports complete data of evaluating the impact of ACTEMRA is the inhibition of structural joint damage in 2009.